ANTIVIRAL PHARMACEUTICAL COMPOSITION
Pharmaceutical compositions are described comprising fucoidan for use in a method for the treatment or the prevention, by intranasal administration, of coronavirus infection in a human. Particularly, the viral infection is OC43 or SARS-CoV-1 or SARS-CoV-2 infection. There are also described Pharmaceutical compositions comprising fucoidan for use in a method for prevention coronavirus spread in a human population, wherein subjects of the population are tested for infection with OC43 or SARS-CoV-1 or SARS-CoV-2 and infected subjects are treated with intranasal administration of the Pharmaceutical composition.
1 . Pharmaceutical composition comprising fucoidan for use in a method for the treatment or the prevention, by intranasal administration, of coronavirus infection in a human.
2 . Pharmaceutical composition for use according to claim 1 , wherein the coronavirus infection is an infection with OC43 or SARS-CoV-2 or SARS-CoV-1.
3 . Pharmaceutical composition for use according to claim 2 , wherein the coronavirus infection is an infection with SARS-CoV-2.
4 . Pharmaceutical composition for use according to claim 1 , wherein the coronavirus infection is an infection with a coronavirus that binds electrostatically to fucoidan.
5 . Pharmaceutical composition for use according to claim 1 , wherein the coronavirus infection is an infection with a coronavirus that has a positive net charge in a receptor binding region.
6 . Pharmaceutical composition for use according to claim 5 , wherein the coronavirus infection is an infection with a coronavirus that has a positive net charge of at least 5 in a in a receptor binding region of the spike protein.
7 . Pharmaceutical composition for use according to claim 1 , wherein the composition is a nasal spray.
8 . Pharmaceutical composition for use according to claim 1 , wherein the pharmaceutical composition is an aqueous solution.
9 . Pharmaceutical composition for use according to claim 1 , wherein the composition comprises 0.1% to 2.7% (w/w) fucoidan.
10 . Pharmaceutical composition for use according to claim 1 , wherein the composition comprises 0.25% to 1.8% (w/w) fucoidan.
11 . Pharmaceutical composition for use according to claim 1 , wherein the composition comprises 0.5 to 1% (w/w) fucoidan.
12 . Pharmaceutical composition according to claim 8 , wherein the pharmaceutical composition comprises a sodium chloride solution.
13 . Pharmaceutical composition for use according to claim 8 , wherein the aqueous solution is isotonic.
14 . Pharmaceutical composition for use according to claim 1 , wherein the pharmaceutical composition is administered intranasally two or three times daily into each nostril of a subject.
15 . Pharmaceutical composition for use according to claim 1 , wherein the pharmaceutical composition is administered in a dose of 1 mg to 4 mg fucoidan into each nostril of a subject per administration.
16 . Pharmaceutical composition for use according to claim 1 , wherein the fucoidan is an extract of Undaria pinnatifida.
17 . Pharmaceutical composition for use according to claim 1 , wherein the fucoidan has an average molecular weight from 50 kDa to 120 kDa, determined by size exclusion chromatography, with a mobile phase comprising 150 mM NaCl and having pH 6.
18 . Pharmaceutical composition for use according to claim 17 , wherein the fucoidan has an average molecular weight from 70 kDa to 105 kDa, determined by size exclusion chromatography, with a mobile phase comprising 150 mM NaCl and having pH 6.
19 . Pharmaceutical composition for use according to claim 1 , wherein the fucoidan has an average molecular weight of 150 kDa and a lower molecular weight cut-off of 10 kDa.
20 . Pharmaceutical composition for use according to claim 1 , wherein the fucoidan has a sulfate content of 20% to 40%.
21 . Pharmaceutical composition for use according to claim 1 , wherein the pharmaceutical composition is administered to nasal epithelium of a subject.
22 . Pharmaceutical composition for use according to claim 1 , wherein the pharmaceutical composition is administered as two doses every 24 hours, the two doses being administered eight hours apart.
23 . Pharmaceutical composition for use according to claim 1 , wherein the method of treatment comprises reduction of viral load in a subject.
24 . Pharmaceutical composition for use according to claim 23 , wherein the viral load is determined by RT-PCR, performed on a nasal swab specimen from the subject.
25 . Pharmaceutical composition for use according to claim 1 , wherein the method of treatment comprises reducing viral genome copy number in a subject.
26 . Pharmaceutical composition for use according claim 1 , wherein the method of treatment comprises reducing the risk of severe symptoms of COVID-19.
27 . Pharmaceutical composition for use according to claim 1 , wherein the method of treatment comprises preventing progressing of severity of COVID-19.
28 . A method of treating or preventing coronavirus infection, comprising intranasally administering to a mammalian subject in need thereof a pharmaceutically effective amount of a pharmaceutical composition comprising fucoidan.
29 . Pharmaceutical composition comprising fucoidan for use in a method of preventing coronavirus spread in a human population, wherein subjects of the population are tested for infection with OC43 or SARS-CoV-2 and infected subjects are treated with intranasal administration of the pharmaceutical composition.
30 . Pharmaceutical composition comprising fucoidan for use in a method of preventing coronavirus spread in a human population wherein subjects who have been identified as being at a high risk of infection are treated with intranasal administration of the pharmaceutical composition.